BRIGHAM MICHAEL F Form SC 13D February 02, 2009

### **UNITED STATES**

### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# **SCHEDULE 13D**

Under the Securities Exchange Act of 1934

(Amendment No. \_\_\_\_\_)\*

# **ImmuCell Corporation**

(Name of Issuer)

Common Stock, par value \$0.10 per share

(Title of Class of Securities)

452525306

(CUSIP Number)

Michael F. Brigham, President and CEO

**ImmuCell Corporation** 

56 Evergreen Drive

### Portland, ME 04103

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

### **February 2, 2009**

#### (Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. x

**Note**: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No 452	52530	06	Page 2 of 4
(1) Names of	f Repo	orting Persons. I.R.S. Identification Nos. of above persons (entities only).	
		nael F. Brigham ropriate Box if a Member of a Group (See Instructions)	
(b) " (3) SEC Use	Only		
(4) Source of	f Funds	ls (See Instructions)	
	P F Disclo	osure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)	
(6) Citizensh	ip or F	Place of Organization	
	USA (7)	Sole Voting Power	
Number of Shares	(8)	202,870 Shared Voting Power	
Beneficially Owned by Each	(9)	n/a Sole Dispositive Power	
Reporting Person With	(10)	202,870 Shared Dispositive Power	
(11) Aggregat	e Amo	n/a ount Beneficially Owned by Each Reporting Person	

202,870

- (12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
- (13) Percent of Class Represented by Amount in Row (11)

6.8%

(14) Type of Reporting Person (See Instructions)

ΙN

Item 1. Security and Issuer. Common stock, par value \$0.10 per share
ImmuCell Corporation
56 Evergreen Drive
Portland, ME 04103
Item 2. Identity and Background. a) Michael F. Brigham
b) c/o ImmuCell Corporation
56 Evergreen Drive
Portland, ME 04103
c) President and CEO of ImmuCell Corporation
d) This person has not been convicted in a criminal proceeding during the last five years
e) This person was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction during the last five years.
f) USA
Item 3. Source and Amount of Funds or Other Consideration.  The source of the \$152,708 used to acquire the common stock is personal funds of the reporting person.
Item 4. Purpose of Transaction. The purpose of the acquisition is personal investment.
Item 5. Interest in Securities of the Issuer.  The 202,870 shares, which represents 6.8% of the outstanding common stock, include 100,000 shares subject to stock options that are currentle exercisable.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.  n/a

Item 7.

n/a

Material to be Filed as Exhibits.

This Schedule 13D is filed in lieu of and replaces previously filed Schedule 13G s.

### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true and correct.

Dated as of February 2, 2009

/s/ Michael F. Brigham Name: Michael F. Brigham Title: President and CEO